Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed N.V. (Nasdaq: AFMD) announced it will release its third quarter 2024 financial results and corporate update on Thursday, November 14, 2024. The clinical-stage immuno-oncology company will host a conference call at 8:30 a.m. EST / 14:30 CET. Investors can access the live audio webcast through the company's website and participate in the call via phone by registering through the provided link. A replay will be available for 30 days following the call.
Affimed N.V. (Nasdaq: AFMD) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale giovedì 14 novembre 2024. L'azienda clinica specializzata in immuno-oncologia organizzerà una conference call alle 8:30 EST / 14:30 CET. Gli investitori possono accedere alla trasmissione audio in diretta tramite il sito web dell'azienda e partecipare alla chiamata per telefono registrandosi attraverso il link fornito. Una registrazione sarà disponibile per 30 giorni dopo la chiamata.
Affimed N.V. (Nasdaq: AFMD) anunció que publicará sus resultados financieros del tercer trimestre de 2024 y una actualización corporativa el jueves 14 de noviembre de 2024. La compañía de oncología inmunitaria en etapa clínica realizará una llamada conferencia a las 8:30 a.m. EST / 14:30 CET. Los inversores pueden acceder a la transmisión de audio en vivo a través del sitio web de la empresa y participar en la llamada por teléfono registrándose a través del enlace proporcionado. Una repetición estará disponible durante 30 días después de la llamada.
Affimed N.V. (Nasdaq: AFMD)는 2024년 3분기 재무 결과 및 기업 업데이트를 2024년 11월 14일 목요일에 발표할 것이라고 발표했습니다. 임상 단계의 면역 종양학 회사는 동부 표준시(EST) 기준 오전 8시 30분 / 중앙 유럽 시간(CET) 기준 오후 2시 30분에 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 회사 웹사이트를 통해 실시간 오디오 웹캐스트에 접속할 수 있으며 제공된 링크를 통해 전화로 참여할 수 있습니다. 통화 후 30일간 재생이 가능합니다.
Affimed N.V. (Nasdaq: AFMD) a annoncé qu'elle publiquera ses résultats financiers du troisième trimestre 2024 et une mise à jour d'entreprise le jeudi 14 novembre 2024. L'entreprise en phase clinique spécialisée en immuno-oncologie organisera une conférence téléphonique à 8h30 EST / 14h30 CET. Les investisseurs peuvent accéder à la diffusion audio en direct via le site web de l'entreprise et participer à l'appel par téléphone en s'inscrivant via le lien fourni. Un replay sera disponible pendant 30 jours après l'appel.
Affimed N.V. (Nasdaq: AFMD) gab bekannt, dass das Unternehmen seine finanziellen Ergebnisse für das dritte Quartal 2024 und ein Unternehmensupdate am Donnerstag, den 14. November 2024 veröffentlichen wird. Das klinische Immunonkologie-Unternehmen wird um 8:30 Uhr EST / 14:30 Uhr CET eine Telefonkonferenz veranstalten. Investoren können über die Unternehmenswebsite auf den Live-Audio-Webcast zugreifen und sich telefonisch über den bereitgestellten Link zur Teilnahme registrieren. Eine Aufzeichnung wird 30 Tage nach dem Anruf verfügbar sein.
- None.
- None.
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.
The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://register.vevent.com/register/BIb9251d6bc6504a4da37a53cdb1b0ac94, and you will be provided with dial-in details and a pin number.
Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will be accessible at the same link for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
FAQ
When will Affimed (AFMD) report Q3 2024 earnings?
What time is Affimed's (AFMD) Q3 2024 earnings call?
How can I access Affimed's (AFMD) Q3 2024 earnings call?
